Payment overview · 2025
General Payments
$444.89
20 reported records · 9 companies
Healthcare provider profile · identity verified
Robert Jackson Williams, MD
Allopathic & Osteopathic Physicians|Family Medicine · LINCOLNTON, GA · NPI 1548202401
Verified facts
What the public records show
CMS Open Payments records show Robert Jackson Williams, MD received $444.89 in general payments during 2025 across 20 reported records.
Medtronic, Inc. accounted for 46.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$205.24 | 46.1% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.90 | 15.9% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $41.30 | 9.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.10 | 8.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.00 | 6.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.58 | 5.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.25 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.62 | 3.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4.90 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $444.89 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $115.87 | 6 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $89.37 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $70.90 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $55.31 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $41.30 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $38.10 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.00 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $4.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
35 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
38 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 902 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 720 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 670 | 100 |
| Gabapentin | Gabapentin | 649 | 87 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 555 | 72 |
| Lisinopril | Lisinopril | 502 | 81 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 461 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 452 | 73 |
| Omeprazole | Omeprazole | 405 | 61 |
| Metformin Hcl | Metformin Hcl | 389 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 363 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 355 | 70 |
| Furosemide | Furosemide | 346 | 72 |
| Famotidine | Famotidine | 329 | 32 |
| Potassium Chloride | Potassium Chloride | 320 | 57 |
| Carvedilol | Carvedilol | 319 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 310 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 285 | 42 |
| Trazodone Hcl | Trazodone Hcl | 278 | 38 |
| Eliquis | Apixaban | 273 | 45 |
| Tramadol Hcl | Tramadol Hcl | 263 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 252 | 33 |
| Sertraline Hcl | Sertraline Hcl | 234 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 233 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 224 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 221 | 19 |
| Divalproex Sodium | Divalproex Sodium | 202 | 17 |
| Azithromycin | Azithromycin | 193 | 124 |
| Diclofenac Sodium | Diclofenac Sodium | 193 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 48 |
| Donepezil Hcl | Donepezil Hcl | 188 | 28 |
| Losartan Potassium | Losartan Potassium | 185 | 39 |
| Allopurinol | Allopurinol | 175 | 40 |
| Pregabalin | Pregabalin | 162 | 22 |
| Lorazepam | Lorazepam | 161 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 155 | 29 |
| Clonidine Hcl | Clonidine Hcl | 152 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 152 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 41 |
| Meloxicam | Meloxicam | 148 | 34 |
| Atenolol | Atenolol | 145 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | suppressed |
| Simvastatin | Simvastatin | 138 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 125 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 119 | 25 |
| Levetiracetam | Levetiracetam | 117 | 18 |
| Memantine Hcl | Memantine Hcl | 117 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 116 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 17 |
| Valsartan | Valsartan | 114 | suppressed |
| Mirtazapine | Mirtazapine | 109 | 20 |
| Risperidone | Risperidone | 107 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 103 | 83 |
| Ondansetron Odt | Ondansetron | 97 | 31 |
| Buspirone Hcl | Buspirone Hcl | 92 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 92 | suppressed |
| Finasteride | Finasteride | 92 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 92 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 12 |
| Diazepam | Diazepam | 88 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 88 | 59 |
| Baclofen | Baclofen | 86 | 12 |
| Clonazepam | Clonazepam | 86 | 14 |
| Methylprednisolone | Methylprednisolone | 85 | 63 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 80 | 47 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 80 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 78 | 22 |
| Glipizide | Glipizide | 77 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 15 |
| Montelukast Sodium | Montelukast Sodium | 70 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 69 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 12 |
| Estradiol | Estradiol | 69 | 15 |
| Xarelto | Rivaroxaban | 69 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 12 |
| Metformin Hcl Er | Metformin Hcl | 65 | suppressed |
| Torsemide | Torsemide | 65 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 64 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 21 |
| Amoxicillin | Amoxicillin | 62 | 37 |
| Jardiance | Empagliflozin | 62 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 40 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | suppressed |
| Ozempic | Semaglutide | 61 | suppressed |
| Ibuprofen | Ibuprofen | 59 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 59 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | suppressed |
| Fluconazole | Fluconazole | 53 | 24 |
| Methimazole | Methimazole | 53 | 11 |
| Haloperidol | Haloperidol | 52 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 51 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 51 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 50 | suppressed |
| Olanzapine | Olanzapine | 49 | suppressed |
| Prednisone | Prednisone | 49 | 14 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 48 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 48 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 48 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 47 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 11 |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Lovastatin | Lovastatin | 44 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 44 | suppressed |
| Bumetanide | Bumetanide | 43 | suppressed |
| Spironolactone | Spironolactone | 42 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 39 | 11 |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Rexulti | Brexpiprazole | 39 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 38 | 27 |
| Temazepam | Temazepam | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 21 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 35 | 35 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Cephalexin | Cephalexin | 34 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 22 |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 16 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Linzess | Linaclotide | 33 | 15 |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 27 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 19 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Insulin Lispro | Insulin Lispro | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 16 | 15 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 11 |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Tivicay | Dolutegravir Sodium | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $444.89 · 20 records | Medtronic, Inc. | CAPLYTA, INGREZZA, INTERSTIM, MINIMED 780G, MOUNJARO, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error